Loading clinical trials...

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Phase 2 Study Of SU011248 As Consolidation Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

NCT00113516•Pfizer

View on ClinicalTrials.gov

Summary

The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with locally advanced and metastatic Non Small Cell Lung Cancer (NSCLC).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically proven NSCLC
•Stage IIIB (locally advanced with malignant effusion) or Stage IV disease
•No prior therapy for NSCLC
•Evidence of unidimensionally measurable disease

Exclusion Criteria

•Previous treatment with systemic chemotherapy for lung cancer
•History of or known brain metastases
•NCI CTCAE Grade 3 hemorrhage within 4 weeks of starting study treatment
•Evidence of hemoptysis within 4 weeks of starting study treatment
•Serious acute or chronic illness or recent history of significant cardiac abnormality
•Previous treatment with anti-angiogenesis agents including thalidomide, or inhibitors of EGFR and PDGFR

Locations (31)

Pfizer Investigational Site

Los Angeles, California, United States

Pfizer Investigational Site

Newark, Delaware, United States

Pfizer Investigational Site

Newark, Delaware, United States

Pfizer Investigational Site

Wilmington, Delaware, United States

Pfizer Investigational Site

Maywood, Illinois, United States

Pfizer Investigational Site

Jeffersonville, Indiana, United States

Pfizer Investigational Site

Louisville, Kentucky, United States

Pfizer Investigational Site

Louisville, Kentucky, United States

Pfizer Investigational Site

Louisville, Kentucky, United States

Pfizer Investigational Site

Shelbyville, Kentucky, United States

Key Dates

Start Date

September 1, 2005

Primary Completion Date

March 1, 2009

Completion Date

March 1, 2009

Last Updated

May 18, 2010

Enrollment

ACTUAL participants

Conditions

Non-small Cell Lung Cancer

Interventions

carboplatin

DRUG

paclitaxel

DRUG

sunitinib

DRUG

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754

Non-small Cell Lung Cancer (NSCLC)

View study

RECRUITINGPHASE3

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248

Non-small Cell Lung Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 18, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Inclusion Criteria

Exclusion Criteria

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)